5 Stocks The Best Performing Hedge Funds Are Piling Into

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNYis another stock that’s off to a tremendous start to the year, posting 45.7% gains. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) does still has some ways to go to get back to its pre-October 2016 levels, when it was trading for well over $70 a share. The company’s announcement that it would discontinue the development of revusiran caused shares to implode by nearly 50% on October 6. They’ve since regained 50% of those losses. Some top hedge funds were buyers in the fourth quarter following the collapse and have been greatly rewarded for their moves, including Eli Casdin‘s Casdin Capital (46,000 shares, lifting its holding to 85,000 shares) and Great Point Partners (new position of 51,935 shares).

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is now focused on the development of patisiran and fitusiran, its most advanced compounds, in addition to having several other drugs in early-stage testing. Alnylam has a global development and commercialization agreement for patisiran and other RNAi therapeutics in place with Sanofi SA (ADR) (NYSE:SNY).

Follow Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY)